Androxal Passes First 'Testes'; Next Phase III Enrolled by May
Repros Therapeutics Inc.'s first pivotal study, called ZA-301, with the hypogonadism therapy Androxal (enclomiphene) hit both of its primary endpoints – testosterone and sperm count – in the intent-to-treat population, as mandated by the FDA, and CEO Joseph Podolski said the $2 billion demand for such therapies could get bigger than the market for erectile dysfunction drugs.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter